Related references
Note: Only part of the references are listed.Identification of glypican-3-derived long peptides activating both CD8+ and CD4+ T cells; prolonged overall survival in cancer patients with Th cell response
Mohammad A. Sayem et al.
ONCOIMMUNOLOGY (2016)
Dendritic Cell-Based Immunotherapy: State of the Art and Beyond
Kalijn F. Bol et al.
CLINICAL CANCER RESEARCH (2016)
An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs
Masatoshi Hirayama et al.
ONCOIMMUNOLOGY (2016)
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma
Deepa K. Krishnadas et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses
Yasuharu Nishimura et al.
CANCER SCIENCE (2015)
TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity
Jennifer D. Stone et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Therapeutic cancer vaccines
Cornelis J. M. Melief et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Beatriz M. Carreno et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy
Yanping Xiao et al.
CANCER DISCOVERY (2015)
Trial Watch: Peptide-based anticancer vaccines
Jonathan Pol et al.
ONCOIMMUNOLOGY (2015)
Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS
Yoshihiro Yoshitake et al.
CLINICAL CANCER RESEARCH (2015)
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma
Carsten Linnemann et al.
NATURE MEDICINE (2015)
Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients
Yusuke Tomita et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients
Hisae Iinuma et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Clinical use of dendritic cells for cancer therapy
Sebastien Anguille et al.
LANCET ONCOLOGY (2014)
A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide
Athanasios Kotsakis et al.
LUNG CANCER (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Mahesh Yadav et al.
NATURE (2014)
Therapeutic vaccines for cancer: an overview of clinical trials
Ignacio Melero et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Classification of current anticancer immunotherapies
Lorenzo Galluzzi et al.
ONCOTARGET (2014)
Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand-Peptide Conjugates
Gijs G. Zom et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Identification of immunogenic LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes and eliciting CD4+ T-cell immunity in patients with malignant disease
Yusuke Tomita et al.
ONCOIMMUNOLOGY (2014)
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
Jaikumar Duraiswamy et al.
CANCER RESEARCH (2013)
Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4+ and CD8+ T-cell Epitopes: KIF20A-Specific CD4+ T-cell Immunity in Patients with Malignant Tumor
Yusuke Tomita et al.
CLINICAL CANCER RESEARCH (2013)
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
Nienke van Rooij et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer
Hiroyuki Suzuki et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
Mariette I. E. van Poelgeest et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
T-helper-1-cell cytokines drive cancer into senescence
Heidi Braumueller et al.
NATURE (2013)
ADOPTIVE CELL THERAPY Honing that killer instinct
Courtney Humphries
NATURE (2013)
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Paul F. Robbins et al.
NATURE MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients
Ryuji Okuyama et al.
ONCOIMMUNOLOGY (2013)
Trial Watch Dendritic cell-based interventions for cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
Immunotherapy of cancer in 2012
John M. Kirkwood et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Exploiting the Mutanome for Tumor Vaccination
John C. Castle et al.
CANCER RESEARCH (2012)
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Paul Sabbatini et al.
CLINICAL CANCER RESEARCH (2012)
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens
Koji Kono et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter et al.
NATURE MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting the tumor mutanome for personalized vaccination therapy
Sebastian Kreiter et al.
ONCOIMMUNOLOGY (2012)
Cross-presentation by dendritic cells
Olivier P. Joffre et al.
NATURE REVIEWS IMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells
Yusuke Tomita et al.
CANCER SCIENCE (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients
Jon Amund Kyte et al.
CLINICAL CANCER RESEARCH (2011)
Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial
Paal Fr. Brunsvig et al.
CLINICAL CANCER RESEARCH (2011)
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Douglas J. Schwartzentruber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T Lymphocytes
Rinke Bos et al.
CANCER RESEARCH (2010)
Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma
Ying Xie et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
Sergio A. Quezada et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells
Violaine Francois et al.
CANCER RESEARCH (2009)
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial
Ninke Leffers et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Mary L. Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia.
Gemma G. Kenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation
Martijn S. Bijker et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL
Michiko Harao et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines
Cornelis J. M. Melief et al.
NATURE REVIEWS CANCER (2008)
Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas
Nobuhisa Ishikawa et al.
CANCER RESEARCH (2007)
Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy
Takako Suda et al.
CANCER SCIENCE (2007)
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity
Martijn S. Bijker et al.
JOURNAL OF IMMUNOLOGY (2007)
Opinion - Building better magic bullets - improving unconjugated monoclonal antibody therapy for cancer
Louis M. Weiner
NATURE REVIEWS CANCER (2007)
Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA
Koji Teramoto et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis
Satoshi Hayama et al.
CANCER RESEARCH (2006)
T helper lymphocytes rescue CTL from activation-induced cell death
Richard Kennedy et al.
JOURNAL OF IMMUNOLOGY (2006)
Identification of HLA-A2-or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma
H Komori et al.
CLINICAL CANCER RESEARCH (2006)
A novel strategy for the discovery of MHC class II-restricted tumor antigens:: Identification of a melanotransferrin helper T-cell epitope
TA Röhn et al.
CANCER RESEARCH (2005)
Dendritic cells as therapeutic vaccines against cancer
J Banchereau et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection
T Nakamura et al.
ONCOGENE (2004)
Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells
K Chamoto et al.
CANCER RESEARCH (2004)
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
EM Janssen et al.
NATURE (2003)
Cancer immunotherapy with peptide-based vaccines: What have we achieved? - Where are we going?
G Parmiani et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray
A Saito-Hisaminato et al.
DNA RESEARCH (2002)
Share Paper
